We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
Cap. Flow
+$505M
Cap. Flow %
0.65%
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51

Top Buys

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$83.5M
2
SPGI icon
S&P Global
SPGI
+$73.5M
3
TSLA icon
Tesla
TSLA
+$55.8M
4
MSFT icon
Microsoft
MSFT
+$45.9M
5
AMZN icon
Amazon
AMZN
+$27.9M

Sector Composition

Rank Sector Weight
1 Technology 24.74%
2 Financials 13.53%
3 Healthcare 13.01%
4 Consumer Discretionary 11.66%
5 Industrials 8.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LZ icon
2226
LegalZoom.com
LZ
$973M
$793K ﹤0.01%
56,063
+39,209
+233% +$590K
MBWM icon
2227
Mercantile Bank Corp
MBWM
$1.05B
$788K ﹤0.01%
22,234
-1,960
-8% -$73.3K
SP
2228
DELISTED
SP Plus Corporation
SP
$785K ﹤0.01%
25,031
-567
-2% -$16.4K
ACRE
2229
Ares Commercial Real Estate
ACRE
$256M
$783K ﹤0.01%
50,461
-4,791
-9% -$70.4K
DCO icon
2230
Ducommun
DCO
$2.94B
$776K ﹤0.01%
14,811
-1,687
-10% -$80.4K
STEL
2231
DELISTED
Stellar Bancorp
STEL
$776K ﹤0.01%
25,022
-2,392
-9% -$72.8K
BNGO icon
2232
Bionano Genomics
BNGO
$13.3M
$775K ﹤0.01%
501
+11
+2% +$14.8K
KZR
2233
DELISTED
Kezar Life Sciences
KZR
$773K ﹤0.01%
4,652
+605
+15% +$86.8K
ATRS
2234
DELISTED
Antares Pharma, Inc.
ATRS
$773K ﹤0.01%
188,475
-138
-0.1% -$501
ASPN icon
2235
Aspen Aerogels
ASPN
$521M
$771K ﹤0.01%
22,371
+2,664
+14% +$86.5K
BAND
2236
Bandwidth Inc
BAND
$1.7B
$771K ﹤0.01%
23,790
+415
+2% +$19.9K
GRBK icon
2237
Green Brick Partners
GRBK
$3.03B
$771K ﹤0.01%
39,010
-2,315
-6% -$53.5K
ALLO icon
2238
Allogene Therapeutics
ALLO
$725M
$769K ﹤0.01%
84,418
-5,503
-6% -$57.3K
ALTO icon
2239
Alto Ingredients
ALTO
$328M
$768K ﹤0.01%
112,581
+13,647
+14% +$76.4K
LYLT
2240
DELISTED
Loyalty Ventures Inc. Common Stock
LYLT
$767K ﹤0.01%
46,407
-815
-2% -$20.2K
LASR icon
2241
nLIGHT
LASR
$2.88B
$766K ﹤0.01%
44,184
+2,672
+6% +$50.3K
SGMO
2242
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$765K ﹤0.01%
131,705
-8,249
-6% -$49K
LYEL icon
2243
Lyell Immunopharma
LYEL
$351M
$764K ﹤0.01%
7,569
+6,404
+550% +$776K
FMBH icon
2244
First Mid Bancshares
FMBH
$1.36B
$761K ﹤0.01%
19,778
-1,982
-9% -$81.5K
BV icon
2245
BrightView Holdings
BV
$1.05B
$758K ﹤0.01%
55,696
-140
-0.3% -$1.89K
SPNS
2246
DELISTED
Sapiens International
SPNS
$757K ﹤0.01%
29,814
+796
+3% +$23.2K
BHR
2247
Braemar Hotels & Resorts
BHR
$139M
$754K ﹤0.01%
122,024
+22,052
+22% +$126K
WTTR icon
2248
Select Water Solutions
WTTR
$2.69B
$754K ﹤0.01%
88,008
-1,359
-2% -$10.6K
UFI icon
2249
UNIFI
UFI
$129M
$752K ﹤0.01%
41,560
-989
-2% -$19.6K
NWLI
2250
DELISTED
National Western Life Group, Inc. Class A
NWLI
$750K ﹤0.01%
3,566
-321
-8% -$68.5K

Similar funds

RhumbLine Advisers's Q1 2022 Portfolio in Review

As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
  • RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
  • RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
  • RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
  • RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
  • RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
  • RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.

Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.